Praveen Kumar Marimuthu/LinkedIn
May 29, 2025, 17:28
Praveen Kumar Marimuthu: RWD Shows NACT Plus Immunotherapy Nearly Doubles pCR in MIBC
Praveen Kumar Marimuthu, Assistant Professor of Medical Oncology at Christian Medical College and Hospital, shared a post on X about a paper by Xinjia Ding et al. published in Scientific Reports:
“Real-world data in Muscle invasive bladder cancer shows that NACT plus immunotherapy (Tislelizumab/pembro) nearly doubled pCR vs chemo alone (48.3% vs 25.4%) and improved downstaging (76% vs 48%).”
Title: Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in muscle-invasive bladder cancer
Authors: Xinjia Ding, Chao Liu, Xiaohui Li, Zhigao Wang, Yanping Wu, Yi Song, Wei Yu, Shikai Wu
You can read the Full Article in Scientific Reports.
More posts featuring Praveen Kumar Marimuthu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 17:28
May 29, 2025, 16:50